Achromobacter Infections and Treatment Options

被引:109
作者
Isler, Burcu [1 ]
Kidd, Timothy J. [2 ,3 ]
Stewart, Adam G. [1 ,4 ]
Harris, Patrick [1 ]
Paterson, David L. [1 ,4 ]
机构
[1] Univ Queensland, Fac Med, UQ Ctr Clin Res, Brisbane, Qld, Australia
[2] Royal Brisbane & Womens Hosp, Pathol Queensland, Cent Microbiol, Brisbane, Qld, Australia
[3] Univ Queensland, Fac Sci, Sch Chem & Mol Biosci, Brisbane, Qld, Australia
[4] Royal Brisbane & Womens Hosp, Infect Dis Unit, Brisbane, Qld, Australia
关键词
Achromobacter; antibiotic resistance; cefiderocol; eravacycline; METALLO-BETA-LACTAMASE; GRAM-NEGATIVE BACILLI; DENITRIFICANS SUBSP XYLOSOXIDANS; DESORPTION IONIZATION-TIME; CYSTIC-FIBROSIS PATIENTS; IN-VITRO SUSCEPTIBILITY; SP NOV; PSEUDOMONAS-AERUGINOSA; AMINOGLYCOSIDE RESISTANCE; MASS-SPECTROMETRY;
D O I
10.1128/AAC.01025-20
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Achromobacter is a genus of nonfermenting Gram-negative bacteria under order Burkholderiales. Although primarily isolated from respiratory tract of people with cystic fibrosis, Achromobacter spp. can cause a broad range of infections in hosts with other underlying conditions. Their rare occurrence and everchanging taxonomy hinder defining their clinical features, risk factors for acquisition and adverse outcomes, and optimal treatment. Achromobacter spp. are intrinsically resistant to several antibiotics (e.g., most cephalosporins, aztreonam, and aminoglycosides), and are increasingly acquiring resistance to carbapenems. Carbapenem resistance is mainly caused by multidrug efflux pumps and metallo-beta-lactamases, which are not expected to be overcome by new beta-lactamase inhibitors. Among the other new antibiotics, cefiderocol, and eravacycline were used as salvage therapy for a limited number of patients with Achromobacter infections. In this article, we aim to give an overview of the antimicrobial resistance in Achromobacter species, highlighting the possible place of new antibiotics in their treatment.
引用
收藏
页数:16
相关论文
共 105 条
  • [1] Synthesis and Spectrum of the Neoglycoside ACHN-490
    Aggen, James B.
    Armstrong, Eliana S.
    Goldblum, Adam A.
    Dozzo, Paola
    Linsell, Martin S.
    Gliedt, Micah J.
    Hildebrandt, Darin J.
    Feeney, Lee Ann
    Kubo, Aya
    Matias, Rowena D.
    Lopez, Sara
    Gomez, Marcela
    Wlasichuk, Kenneth B.
    Diokno, Raymond
    Miller, George H.
    Moser, Heinz E.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (11) : 4636 - 4642
  • [2] Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003)
    Aisenberg, G
    Rolston, KV
    Safdar, A
    [J]. CANCER, 2004, 101 (09) : 2134 - 2140
  • [3] Comparison of Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry Platforms for the Identification of Gram-Negative Rods from Patients with Cystic Fibrosis
    Alby, Kevin
    Gilligan, Peter H.
    Miller, Melissa B.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (11) : 3852 - 3854
  • [4] In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods
    Almuzara, Marisa
    Limansky, Adriana
    Ballerini, Viviana
    Galanternik, Laura
    Famiglietti, Angela
    Vay, Carlos
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (01) : 68 - 71
  • [5] Comparative Activities of Tigecycline and Other Tetracyclines against Nonfermenting Gram-Negative Bacilli, Excluding Acinetobacter spp.
    Almuzara, Marisa N.
    Encalada Barzallo, Maria Isabel
    Famiglietti, Angela M. R.
    Vay, Carlos A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (08) : 3961 - 3963
  • [6] Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non- respiratory samples
    Amoureux, L.
    Bador, J.
    Verrier, T.
    Mjahed, H.
    De Curraize, C.
    Neuwirth, C.
    [J]. EPIDEMIOLOGY AND INFECTION, 2016, 144 (16) : 3527 - 3530
  • [7] Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137
    Amoureux, Lucie
    Sauge, Juliette
    Sarret, Benoit
    Lhoumeau, Matthieu
    Bajard, Audrey
    Tetu, Jennifer
    Bador, Julien
    Neuwirth, Catherine
    Caillon, Jocelyne
    Cardot-Martin, Emilie
    Cattoir, Vincent
    Doleans-Jordheim, Anne
    Ferroni, Agnes
    Guet-Revillet, Helene
    Hery-Arnaud, Genevieve
    Segonds, Christine
    Thomas, Elise
    Plesiat, Patrick
    Hoang Vu-Thien
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (06) : 804 - 807
  • [8] Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates
    Amoureux, Lucie
    Bador, Julien
    Zouak, Fatma Bounoua
    Chapuis, Angelique
    de Curraize, Claire
    Neuwirth, Catherine
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (04) : 486 - 494
  • [9] Detection of Achromobacter xylosoxidans in Hospital, Domestic, and Outdoor Environmental Samples and Comparison with Human Clinical Isolates
    Amoureux, Lucie
    Bador, Julien
    Fardeheb, Sakina
    Mabille, Cedric
    Couchot, Charlyne
    Massip, Clemence
    Salignon, Anne-Lise
    Berlie, Guillaume
    Varin, Veronique
    Neuwirth, Catherine
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2013, 79 (23) : 7142 - 7149
  • [10] Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: First French data
    Amoureux, Lucie
    Bador, Julien
    Siebor, Eliane
    Taillefumier, Nathalie
    Fanton, Annlyse
    Neuwirth, Catherine
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (02) : 170 - 176